Tarsus Pharmaceuticals (TARS) Retained Earnings (2019 - 2026)
Tarsus Pharmaceuticals (TARS) recorded quarterly Retained Earnings of -$298000.0 in Q1 2026, down 178.22% quarter-over-quarter from $381000.0 in Q4 2025, and up 99.92% on a YoY basis from -$149057.6 in Q1 2025.
Tarsus Pharmaceuticals (TARS) Retained Earnings (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$298000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.92% year-over-year to -$298000.0; the TTM figure through Mar 2026 stood at -$298000.0 (up 99.92% YoY), while the FY2025 annual figure was $381000.0, up 112.85% from the prior year.
- Retained Earnings was -$298000.0 for Q1 2026 at Tarsus Pharmaceuticals, down from $381000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $381000.0 in Q4 2025 to a low of -$418.3 million in Q3 2025.
- Historically, Retained Earnings has averaged -$140.6 million across 5 years, with a median of -$72.7 million in 2022.
- Biggest YoY gain for Retained Earnings was 4425.0% in 2024; the steepest drop was 1363713.04% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$108.8 million in 2022, then plunged by 124.94% to -$244.7 million in 2023, then jumped by 100.07% to $179000.0 in 2024, then surged by 112.85% to $381000.0 in 2025, then plunged by 178.22% to -$298000.0 in 2026.
- The last three Retained Earnings figures came in at -$298000.0 (Q1 2026), $381000.0 (Q4 2025), and -$418.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn | -298,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -298,000.00 |
| Dec 31, 2025 | 381,000.00 |
| Sep 30, 2025 | -418.26 Mn |
| Jun 30, 2025 | -405.67 Mn |
| Mar 31, 2025 | -385.33 Mn |
| Dec 31, 2024 | 179,000.00 |
| Sep 30, 2024 | 346,000.00 |
| Jun 30, 2024 | -313.68 Mn |
| Mar 31, 2024 | -280.39 Mn |
| Dec 31, 2023 | -244.66 Mn |
| Sep 30, 2023 | -8,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Dec 31, 2022 | -108.76 Mn |
| Sep 30, 2022 | -95.16 Mn |
| Jun 30, 2022 | -72.70 Mn |
| Mar 31, 2022 | -66.90 Mn |
| Sep 30, 2021 | -31.82 Mn |
| Jun 30, 2021 | -16.10 Mn |
| Mar 31, 2021 | -22.50 Mn |